Sporadic Hypoparathyroidism Treated with Teriparatide: A Case Report and Literature Review

Abstract

Herein we describe the case of a 64-year-old woman with hypoparathyroidism diagnosed at the age of 40, after an acute episode of tetany and seizures due to severe hypocalcemia. She was treated for more than 20 years with calcitriol and calcium supplementation but she presented with marked hypercalciuria and recently nephrolithiasis, although serum calcium was maintained at levels below normal range. Provided that any attempt to increase the recommended dose of calcitriol was leading to an exacerbation of hypercalciuria, we decided to enroll an alternative tool in the treatment strategy. In order to avoid further deterioration of renal function she was administered once-daily a subcutaneous (sc) injection of synthetic human parathyroid hormone (PTH 1-34) while doses of calcium and calcitriol were gradually decreased depending on the response of calcium metabolism in serum and urine samples taken periodically. Within two months of administration, PTH (1-34) significantly reduced the level of urine calcium excretion compared with calcitriol therapy and maintained serum calcium in the normal range. The relevant literature is reviewed in light of this alternative therapeutic approach in long-standing hypoparathyroidism, illustrating the potential benefits and the unresolved issues in parathyroid hormone replacement.

calcitriol - hypocalcemia - hypercalciuria - hypoparathyroidism - synthetic human parathyroid hormone

References

• 1 Abugassa S, Nordenstrom J, Eriksson S, Sjoden G. Bone mineral density in patients with chronic hypoparathyroidism.  J Clin Endocrinol Metab. 1993;  76 1617-1621
• 2 Angelopoulos NG, Goula A, Rombopoulos G, Kaltzidou V, Katounda E, Kaltsas D, Tolis G. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia.  J Bone Miner Metab. 2006;  24 138-145
• 3 Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK. et al . Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.  J Biol Chem. 2003;  278 50259-50272
• 4 Chan FK, Tiu SC, Choi KL, Choi CH, Kong AP, Shek CC. Increased bone mineral density in patients with chronic hypoparathyroidism.  J Clin Endocrinol Metab. 2003;  88 3155-3159
• 5 Chen Q, Kaji H, Iu M, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects.  J Clin Endocrinol Metab. 2003;  88 4655-4658
• 6 Cheng PT, Chan C, Muller K. Cyclical treatment of osteopenic ovariectomized adult rats with PTH (1-34) and pamidronate.  J Bone Miner Res. 1995;  10 119-126
• 7 Demiralp B, Chen H, Koh-Paige AJ, Keller ET, McCauley LK. Anabolic effects of parathyroid hormone during endochondral bone growth are dependent on c-fos.  Endocrinology. 2002;  143 4038-4047
• 8 Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone.  Endocr Rev. 1993;  14 690-709
• 9 Duan Y, De Luca V, Seeman E. Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone.  J Clin Endocrinol Metab. 1999;  84 718-722
• 10 Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes.  N Engl J Med. 2004;  350 2068-2079
• 11 Fujiyama K, Kiriyama T, Ito M. Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism.  J Clin Endocrinol Metab. 1995;  80 2135-2138
• 12 Goswami R, Brown EM, Kochupillai N, Gupta N, Rani R, Kifor O, Chattopadhyay N. Prevalence of calcium sensing receptor autoantibodies in patients with sporadic idiopathic hypoparathyroidism.  Eur J Endocrinol. 2004;  150 918
• 13 Hock JM, Gera I, Fonesca J, Raisz Human LG. PTH increases rat bone mass in ovariectomized and orchidectomized rats.  Endocrinology. 1998;  122 2899-2904
• 14 Jiang Y, Zhao J, Eriksen EF, Wang O, Genant HK, Mitlak BH. Improved 3-dimensional microstructure of cancellous and cortical bone in a multicenter, double-blind, randomized and placebo controlled study of teriparatide [rhPTH(1-34)].  J Bone Miner Res. 2002;  17 ((Suppl 1)) 135
• 15 Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.  J Clin Invest. 1999;  104 439-446
• 16 Kruse K, Kracht U, Wohlfart K, Kruse U. Biochemical markers of bone turnover, intact serum parathyroid hormone and renal calcium excretion in patients with pseudohypoparathyroidism and hypoparathyroidism before and during vitamin D treatment.  Eur J Pediatr. 1989;  148 535-539
• 17 Langdahl BL, Mortensen L, Vesterby A, Eriksen EF, Charles P. Bone histomorphometry in hypoparathyroid patients treated with vitamin D.  Bone. 1996;  18 103-108
• 18 Li Y, Song YH, Rais N, Connor E, Schatz D, Muir A, Maclaren N. Autoantibodies to the extracellular domain of the calcium sensing receptor inpatients with acquired hypoparathyroidism.  J Clin Invest. 1996;  4 910-914
• 19 Mayer A, Ploix C, Orgiazzi J, Desbos A, Moreira A, Vidal H, Monier JC, Bienvenu J, Fabien N. Calcium-sensing receptor autoantibodies are relevant markers of acquired hypoparathyroidism.  J Clin Endocrinol Metab. 2004;  89 4484-4488
• 20 Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-1 in growing mice.  Endocrinology. 2001;  142 4349-4356
• 21 Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone 1-34 on fractures and bone mineral density in postmenopausal women with osteoporosis.  N Engl J Med. 2001;  344 1434-1441
• 22 Polverosi R, Zambelli C, Sbeghen R. Calcification of the basal nuclei in hypoparathyroidism; the computed and magnetic resonance tomographic aspects.  Radiol Med (Torino). 1994;  87 512
• 23 Ruff RL, Weissmann J. Endocrine myopathies.  Neurol Clin. 1988;  6 575-592
• 24 Sunthornthepvarakul T, Churesigaew S, Ngowngarmratana S. A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism.  J Clin Endocrinol Metab. 1999;  84 3792-3796
• 25 Uusi-Rasi K, Beck TJ, Oreskovic TL, Sato M, Bogado CE, Zanchetta JR. Teriparatide (rhPTH[1-34]) improves the structural geometry of the hip.  J Bone Miner Res. 2002;  17 ((Suppl 1)) 208
• 26 Winer KK, Yanovski JA, Cutler GB. Synthetic human parathyroid hormone 1-34 vs. calcitriol and calcium in the treatment of hypoparathyroidism: results of a randomized crossover trial.  JAMA. 1996;  276 631-636
• 27 Winer KK, Yanovski JA, Sarani B, Cutler GB. A randomized, crossover trial of once daily vs. twice-daily human parathyroid hormone 1-34 in the treatment of hypoparathyroidism.  J Clin Endocrinol Metab. 1998;  83 3480-3486
• 28 Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone- (1-34) versus calcitriol and calcium.  J Clin Endocrinol Metab. 2003;  88 4214-4220

Correspondence